Ourania Tatsis Sells 466 Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Ourania Tatsis sold 466 shares of the stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $460.43, for a total value of $214,560.38. Following the completion of the sale, the executive vice president owned 51,436 shares of the company’s stock, valued at approximately $23,682,677.48. This represents a 0.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Ourania Tatsis also recently made the following trade(s):

• On Wednesday, January 7th, Ourania Tatsis sold 4,500 shares of Vertex Pharmaceuticals stock. The stock was sold at an average price of $474.99, for a total value of $2,137,455.00.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $491.47 on Friday. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.68. The company has a market capitalization of $124.70 billion, a price-to-earnings ratio of 32.06 and a beta of 0.30. The business has a 50-day moving average of $459.98 and a 200-day moving average of $427.76.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing the consensus estimate of $5.05 by ($0.02). The company had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. Vertex Pharmaceuticals had a return on equity of 24.90% and a net margin of 32.94%.The business’s revenue was up 9.5% on a year-over-year basis. During the same period last year, the firm posted $3.98 earnings per share. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Analyst Ratings Changes

VRTX has been the subject of a number of recent analyst reports. Scotiabank raised their price target on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a report on Friday. Weiss Ratings raised shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, February 4th. Oppenheimer upgraded Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $540.00 target price for the company in a research note on Friday. Evercore boosted their price target on Vertex Pharmaceuticals from $475.00 to $530.00 and gave the stock an “outperform” rating in a research note on Friday, January 23rd. Finally, Barclays raised Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $414.00 to $606.00 in a report on Tuesday, January 27th. Twenty-two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $537.05.

Vertex Pharmaceuticals News Roundup

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Revenue and product momentum — Q4 revenue of ~$3.19B (≈+9.5% YoY) came in at or slightly above many forecasts, driven by cystic fibrosis product sales and new launches (Alyftrek, Casgevy, Journavx), supporting near-term cash flow expectations. Article Title
• Positive Sentiment: Analyst upgrade and bullish targets — Oppenheimer upgraded VRTX to “outperform” with a $540 target; several other firms recently raised targets or reiterated buys, which can drive momentum and institutional demand. Article Title
• Positive Sentiment: Pipeline diversification highlighted — Company commentary emphasized growth beyond CF (autoimmune partnerships/expansion), which reduces concentration risk and supports longer-term upside. Article Title
• Neutral Sentiment: 2026 revenue guidance roughly in-line — Management set FY2026 revenue guidance around $13.0–13.1B, largely matching Street expectations; this limits downside from guidance surprises but is not a bullish catalyst on its own. Article Title
• Neutral Sentiment: Full materials available for modeling — The slide deck and earnings call transcript are posted; analysts will parse product trends and margins to update models. Article Title
• Negative Sentiment: Small EPS miss and mixed metric comparisons — EPS was ~$5.03 vs. consensus near $5.05–$5.07; some outlets flagged revenue slightly below certain Street models, triggering near-term profit-taking. Article Title
• Negative Sentiment: Insider selling — Multiple senior executives disclosed open-market sales this week (EVPs, CAO). While common for tax/diversification, the cluster of sales can amplify short-term negative sentiment. Article Title
• Negative Sentiment: After-hours weakness — The EPS miss plus insider sales pressured shares in after-hours trading, reflecting short-term profit-taking before today’s rebound. Article Title

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Kestra Advisory Services LLC raised its stake in Vertex Pharmaceuticals by 0.3% during the fourth quarter. Kestra Advisory Services LLC now owns 14,431 shares of the pharmaceutical company’s stock valued at $6,542,000 after buying an additional 40 shares in the last quarter. Parkside Financial Bank & Trust increased its holdings in shares of Vertex Pharmaceuticals by 44.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,002 shares of the pharmaceutical company’s stock valued at $454,000 after acquiring an additional 308 shares during the last quarter. 1248 Management LLC increased its holdings in shares of Vertex Pharmaceuticals by 4.8% in the 4th quarter. 1248 Management LLC now owns 1,343 shares of the pharmaceutical company’s stock valued at $609,000 after acquiring an additional 62 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Vertex Pharmaceuticals by 9.3% during the 4th quarter. The Manufacturers Life Insurance Company now owns 557,713 shares of the pharmaceutical company’s stock valued at $252,880,000 after acquiring an additional 47,548 shares in the last quarter. Finally, Wimmer Associates 1 LLC lifted its stake in Vertex Pharmaceuticals by 1.3% during the fourth quarter. Wimmer Associates 1 LLC now owns 5,526 shares of the pharmaceutical company’s stock worth $2,505,000 after purchasing an additional 71 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.